Patent · US Active

Niclosamide for the treatment of cancer metastasis

US11331290B2 · kind B2 · utility

0Cited by

0References

15Claims

0Family size

Assignee

Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft · DE

Inventors

Ulrike Stein · Schwanebeck, DE
Wolfgang Walther · Berlin, DE
Ulrike Sack · Berlin, DE
Peter Schlag · Berlin, DE

Key dates

Filing date	Jan 28, 2020
Grant date	May 17, 2022
Priority date	—
Expiry date	Jan 28, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A method for inhibiting, reducing and/or reducing the risk of cancer metastasis in a subject, including identifying a subject as in need of inhibiting, reducing and/or reducing the risk of cancer metastasis, by identifying the subject as having a cancer with an elevated or up-regulated level of S100A4 transcription compared to a level in non-oncogenic cells, and administering to the subject a therapeutically effective amount of niclosamide or a niclosamide derivate, thereby inhibiting or reducing S100A4 transcription, so as to inhibit, reduce and/or reduce the risk of cancer metastasis, wherein 15 to 400 mg niclosamide or niclosamide derivate is administered per kg body weight of the subject (mg/kg), 1 or 2 times daily.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.